Efficacy of sleeve lobectomy after neoadjuvant chemoimmunotherapy in lung cancer: A retrospective cohort study_Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Authors：

WANG Zheng , WANG Meng ,  SUN Daqiang

Department of Thoracic Surgery, Tianjin Chest Hospital Affiliated to Tianjin University, Tianjin, 300222, P. R. China;

Corresponding author：

SUN Daqiang, Email: sdqmdsr@163.com

Keywords：

Lung cancer; sleeve lobectomy; neoadjuvant immunochemotherapy

DOI：

10.7507/1007-4848.202301033

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To evaluate the outcomes of sleeve resection following neoadjuvant chemoimmunotherapy for lung cancer. Methods The clinical data of patients diagnosed with lung cancer and underwent sleeve lobectomy surgery at Tianjin Chest Hospital were retrospectively analyzed. Patients were divided into two groups: a neoadjuvant treatment group and a surgery alone group. The clinical data of two groups were compared. Results Finally 22 patients were collected, including 19 males and 3 females with a median age of 63 years. There were 7 patients in the neoadjuvant treatment group, and 15 patients in the surgery alone group. There was no statistical difference in surgical time, intraoperative bleeding, lymph node dissection, postoperative catheterization time, or postoperative drainage volume between the two groups (P>0.05). In the neoadjuvant treatment group, 1 patient had a second thoracotomy exploration for hemostasis due to bronchial artery bleeding, 2 patients had wound infection, 1 patient had immune-associated pneumonia before surgery, and 1 patient had immune-associated pneumonia before postoperative adjuvant therapy. Postoperative pathological results of patients in the neoadjuvant treatment group showed that 1 (1/7, 14.3%) patient had pathological complete response, and 3 (3/7, 42.9%) patients achieved major pathological response. Conclusion Neoadjuvant chemoimmunotherapy can lead to complications, including operation-related complications and immunotherapy-related complications. However, the degree of postoperative pathological remission is also significantly improved. Overall, sleeve resection following neoadjuvant chemoimmunotherapy can be considered as a treatment option for patients with lung cancer.

Citation： WANG Zheng, WANG Meng, SUN Daqiang. Efficacy of sleeve lobectomy after neoadjuvant chemoimmunotherapy in lung cancer: A retrospective cohort study. Chinese Journal of Clinical Thoracic and Cardiovascular Surgery, 2024, 31(12): 1775-1780. doi: 10.7507/1007-4848.202301033 Copy

1.	Gaissert HA, Mathisen DJ, Moncure AC, et al. Survival and function after sleeve lobectomy for lung cancer. J Thorac Cardiovasc Surg, 1996, 111(5): 948-953.
2.	Tronc F, Grégoire J, Rouleau J, et al. Long-term results of sleeve lobectomy for lung cancer. Eur J Cardiothorac Surg, 2000, 17(5): 550-556.
3.	潘茂杰, 魏煜程. 袖式肺叶切除术在非小细胞肺癌中的应用. 中国胸心血管外科临床杂志, 2018, 25(6): 526-532.Pan MJ, Wei YC. Application of sleeve lobectomy in non-small cell lung cancer. Chin J Clin Thorac Cardiovasc Surg, 2018, 25(6): 526-532.
4.	白悦, 孙大强, 张逊, 等. PD-1抑制剂联合化疗在Ⅲ期非小细胞肺癌术前新辅助治疗中的随机对照研究. 中国胸心血管外科临床杂志, 2021, 28(8): 963-971.Bai Y, Sun DQ, Zhang X, et al. Randomized controlled study of PD-1 inhibitors combined with chemotherapy in neoadjuvant therapy for stage Ⅲ non-small cell lung cancer. Chin J Clin Thorac Cardiovasc Surg, 2021, 28(8): 963-971.
5.	Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med, 2018, 378(21): 1976-1986.
6.	Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med, 2022, 386(21): 1973-1985.
7.	Liang H, Yang C, Gonzalez-Rivas D, et al. Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer. Transl Lung Cancer Res, 2021, 10(1): 143-155.
8.	Chen Y, Zhang L, Yan B, et al. Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer. Transl Lung Cancer Res, 2020, 9(3): 761-767.
9.	Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial. Nat Med, 2021, 27(3): 504-514.
10.	Provencio M, Nadal E, Insa A, et al. OA01. 05 phase Ⅱ study of neo-adjuvant chemo/immunotherapy for resectable stages ⅢA non-small cell lung cancer-NADIM study-SLCG. J Thorac Oncol, 2018, 13(10): S320.
11.	Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg, 2019, 158(1): 269-276.
12.	Bott MJ, Cools-Lartigue J, Tan KS, et al. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg, 2018, 106(1): 178-183.

1. Gaissert HA, Mathisen DJ, Moncure AC, et al. Survival and function after sleeve lobectomy for lung cancer. J Thorac Cardiovasc Surg, 1996, 111(5): 948-953.
2. Tronc F, Grégoire J, Rouleau J, et al. Long-term results of sleeve lobectomy for lung cancer. Eur J Cardiothorac Surg, 2000, 17(5): 550-556.
3. 潘茂杰, 魏煜程. 袖式肺叶切除术在非小细胞肺癌中的应用. 中国胸心血管外科临床杂志, 2018, 25(6): 526-532.Pan MJ, Wei YC. Application of sleeve lobectomy in non-small cell lung cancer. Chin J Clin Thorac Cardiovasc Surg, 2018, 25(6): 526-532.
4. 白悦, 孙大强, 张逊, 等. PD-1抑制剂联合化疗在Ⅲ期非小细胞肺癌术前新辅助治疗中的随机对照研究. 中国胸心血管外科临床杂志, 2021, 28(8): 963-971.Bai Y, Sun DQ, Zhang X, et al. Randomized controlled study of PD-1 inhibitors combined with chemotherapy in neoadjuvant therapy for stage Ⅲ non-small cell lung cancer. Chin J Clin Thorac Cardiovasc Surg, 2021, 28(8): 963-971.
5. Forde PM, Chaft JE, Smith KN, et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med, 2018, 378(21): 1976-1986.
6. Forde PM, Spicer J, Lu S, et al. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer. N Engl J Med, 2022, 386(21): 1973-1985.
7. Liang H, Yang C, Gonzalez-Rivas D, et al. Sleeve lobectomy after neoadjuvant chemoimmunotherapy/chemotherapy for local advanced non-small cell lung cancer. Transl Lung Cancer Res, 2021, 10(1): 143-155.
8. Chen Y, Zhang L, Yan B, et al. Feasibility of sleeve lobectomy after neo-adjuvant chemo-immunotherapy in non-small cell lung cancer. Transl Lung Cancer Res, 2020, 9(3): 761-767.
9. Cascone T, William WN, Weissferdt A, et al. Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: The phase 2 randomized NEOSTAR trial. Nat Med, 2021, 27(3): 504-514.
10. Provencio M, Nadal E, Insa A, et al. OA01. 05 phase Ⅱ study of neo-adjuvant chemo/immunotherapy for resectable stages ⅢA non-small cell lung cancer-NADIM study-SLCG. J Thorac Oncol, 2018, 13(10): S320.
11. Bott MJ, Yang SC, Park BJ, et al. Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non-small cell lung cancer. J Thorac Cardiovasc Surg, 2019, 158(1): 269-276.
12. Bott MJ, Cools-Lartigue J, Tan KS, et al. Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors. Ann Thorac Surg, 2018, 106(1): 178-183.

Chinese Journal of Clinical Thoracic and Cardiovascular Surgery

Efficacy of sleeve lobectomy after neoadjuvant chemoimmunotherapy in lung cancer: A retrospective cohort study

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content